Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus
出版年份 2014 全文链接
标题
Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus
作者
关键词
Metformin, Rosiglitazone, Sulfonylurea, Liraglutide, Insulin Glargine
出版物
DRUGS
Volume 74, Issue 3, Pages 325-351
出版商
Springer Nature
发表日期
2014-01-16
DOI
10.1007/s40265-013-0172-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Complementing Insulin Therapy to Achieve Glycemic Control
- (2013) Anthony H. Barnett ADVANCES IN THERAPY
- Effects of Exenatide on Kidney Function, Adverse Events, and Clinical End Points of Kidney Disease in Type 2 Diabetes
- (2013) Katherine R. Tuttle et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
- (2013) John B. Buse et al. ANNALS OF INTERNAL MEDICINE
- Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy
- (2013) Giuseppe Derosa et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
- (2013) J. Rosenstock et al. DIABETES CARE
- Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
- (2013) Robert R. Henry et al. DIABETES CARE
- Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
- (2013) B. Wang et al. DIABETES OBESITY & METABOLISM
- Exenatide – pharmacokinetics, pharmacodynamics, safety and tolerability in patients >= 75 years of age with Type 2 diabetes
- (2013) H. Linnebjerg et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Variation in Inflammatory Markers and Glycemic Parameters After 12 Months of Exenatide Plus Metformin Treatment Compared with Metformin Alone: A Randomized Placebo-Controlled Trial
- (2013) Giuseppe Derosa et al. PHARMACOTHERAPY
- Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus
- (2013) Sonal Singh et al. JAMA Internal Medicine
- The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m2in Spain
- (2013) Tiago Fonseca et al. JOURNAL OF MEDICAL ECONOMICS
- Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTcinterval in healthy subjects
- (2012) Börje Darpö et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting
- (2012) Manjiri Pawaskar et al. CURRENT MEDICAL RESEARCH AND OPINION
- Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research
- (2012) Concetta Irace et al. Diabetes & Vascular Disease Research
- The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
- (2012) J. Rosenstock et al. DIABETES CARE
- Standards of Medical Care in Diabetes--2013
- (2012) DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks
- (2012) K. Tatarkiewicz et al. DIABETES OBESITY & METABOLISM
- Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
- (2012) T. Ridge et al. DIABETES OBESITY & METABOLISM
- Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting
- (2012) M. Pawaskar et al. DIABETES OBESITY & METABOLISM
- Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment
- (2012) M. S. Fineman et al. DIABETES OBESITY & METABOLISM
- A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo
- (2012) D. A. Scott et al. DIABETES OBESITY & METABOLISM
- Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis
- (2012) M. Pendergrass et al. DIABETES OBESITY & METABOLISM
- Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
- (2012) R. Balena et al. DIABETES OBESITY & METABOLISM
- A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer
- (2012) Carlos Alves et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population
- (2012) John A. Romley et al. Diabetes Technology & Therapeutics
- A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with Type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti
- (2012) R. Violante et al. DIABETIC MEDICINE
- Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes
- (2012) G. Derosa et al. DIABETIC MEDICINE
- Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study
- (2012) M. Wenten et al. DIABETIC MEDICINE
- Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety
- (2012) D. Nathanson et al. DIABETOLOGIA
- Use of Concomitant Glucose-Lowering Therapies and Associated Treatment Results Observed in Clinical Trials of Twice-Daily Exenatide
- (2012) Richard Pencek et al. Endocrine Practice
- Clinical Outcomes of Concomitant Therapy of Exenatide Twice Daily and Basal Insulin in Patients with Type 2 Diabetes Mellitus: A Retrospective Database Analysis in the United States
- (2012) Manjiri Pawaskar et al. Endocrine Practice
- Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1
- (2012) David G Parkes et al. Expert Opinion on Drug Discovery
- Exenatide Alters Myocardial Glucose Transport and Uptake Depending on Insulin Resistance and Increases Myocardial Blood Flow in Patients with Type 2 Diabetes
- (2012) M. Gejl et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
- (2012) Baptist Gallwitz et al. LANCET
- Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus
- (2012) Linong Ji et al. Journal of Diabetes Investigation
- Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany
- (2012) Lesley-Ann Miller et al. JOURNAL OF MEDICAL ECONOMICS
- Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
- (2011) Robert Ratner et al. Cardiovascular Diabetology
- Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents
- (2011) William J. Valentine et al. CLINICAL THERAPEUTICS
- Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting
- (2011) Richard M. Bergenstal et al. CURRENT MEDICAL RESEARCH AND OPINION
- Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia
- (2011) B. Gallwitz et al. DIABETES CARE
- Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*
- (2011) K. Y. Thong et al. DIABETES OBESITY & METABOLISM
- Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study
- (2011) J. K. Berg et al. DIABETES OBESITY & METABOLISM
- A cohort study of acute pancreatitis in relation to exenatide use
- (2011) D. D. Dore et al. DIABETES OBESITY & METABOLISM
- Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study
- (2011) W. E. Schmidt et al. DIABETIC MEDICINE
- Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients
- (2011) Giuseppe Derosa et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland
- (2011) M. Brändle et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- A thorough QT study to evaluate the effects of singledose exenatide 10 μg on cardiac repolarization in healthy subjects
- (2011) H. Linnebjerg et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants
- (2011) Goodarz Danaei et al. LANCET
- Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes
- (2011) Nobuya Inagaki et al. Journal of Diabetes Investigation
- Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy
- (2011) Manjiri D. Pawaskar et al. JOURNAL OF MEDICAL ECONOMICS
- Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID
- (2011) Onur Baser et al. JOURNAL OF MEDICAL ECONOMICS
- Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents
- (2010) Krystyna Tatarkiewicz et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus
- (2010) Eric A. Schwartz et al. ATHEROSCLEROSIS
- Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States
- (2010) Won Chan Lee et al. CLINICAL THERAPEUTICS
- Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired -Cell Function?
- (2010) J. J. Meier et al. DIABETES
- Effects of Exenatide Plus Rosiglitazone on -Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
- (2010) R. A. DeFronzo et al. DIABETES CARE
- Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes
- (2010) J. Koska et al. DIABETES CARE
- Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis
- (2010) R. Garg et al. DIABETES CARE
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
- (2010) J. B. Buse et al. DIABETES CARE
- Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database
- (2010) J. H. Best et al. DIABETES CARE
- A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin
- (2010) J. Liutkus et al. DIABETES OBESITY & METABOLISM
- Exenatide Versus Glibenclamide in Patients with Diabetes
- (2010) G. Derosa et al. Diabetes Technology & Therapeutics
- A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes
- (2010) Walid K.H. Fakhoury et al. PHARMACOLOGY
- Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks
- (2010) Takashi Kadowaki et al. Journal of Diabetes Investigation
- Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes
- (2009) T. Okerson et al. AMERICAN JOURNAL OF HYPERTENSION
- Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: A randomized, placebo-controlled, single-blind, dose-escalation, crossover study
- (2009) Jaret Malloy et al. CLINICAL THERAPEUTICS
- Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea
- (2009) Richard Bergenstal et al. CURRENT MEDICAL RESEARCH AND OPINION
- Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine
- (2009) Rosalind Fabunmi et al. CURRENT MEDICAL RESEARCH AND OPINION
- Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
- (2009) David D. Dore et al. CURRENT MEDICAL RESEARCH AND OPINION
- One-Year Treatment With Exenatide Improves -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial
- (2009) M. C. Bunck et al. DIABETES CARE
- Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting
- (2009) T. Mittendorf et al. DIABETES OBESITY & METABOLISM
- Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting
- (2009) D. I. Brixner et al. DIABETES OBESITY & METABOLISM
- Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study
- (2009) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- Exenatide efficacy and safety: a systematic review
- (2009) S. L. Norris et al. DIABETIC MEDICINE
- Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily
- (2009) J. H. Best et al. DIABETIC MEDICINE
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis
- (2008) Nicole R Pinelli et al. ANNALS OF PHARMACOTHERAPY
- Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom
- (2008) Anette Woehl et al. Cardiovascular Diabetology
- Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
- (2008) T MORETTO et al. CLINICAL THERAPEUTICS
- Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: A randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study
- (2008) Sherwyn L. Schwartz et al. CLINICAL THERAPEUTICS
- Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes
- (2008) Adriana Forti et al. CURRENT MEDICAL RESEARCH AND OPINION
- Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
- (2008) David C. Klonoff et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
- (2008) Ralph A. DeFronzo et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea
- (2008) Yan Gao et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
- (2008) Luc F Van Gaal et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus
- (2008) Prajakti A. Kothare et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
- (2008) Helle Linnebjerg et al. REGULATORY PEPTIDES
- Estimating the Long-Term Cost-Effectiveness of Exenatide in the United States: An Adjunctive Treatment for Type 2 Diabetes Mellitus
- (2007) Michael E. Minshall et al. VALUE IN HEALTH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now